Welcome to our dedicated page for GEMINA LABORATORIES news (Ticker: GLABF), a resource for investors and traders seeking the latest updates and insights on GEMINA LABORATORIES stock.
Gemina Laboratories Ltd. (GLABF), also known as Gemina Labs, is a biosensor, diagnostic and binding technologies company initially focused on the diagnostics industry. Its news flow provides insight into how the company is advancing its proprietary chemistries, building partnerships, and managing its capital structure.
Company news releases describe the development of transformative, patented, proprietary chemistries that power next generation testing platforms for a wide range of pathogens and other analytes that affect human health and wellness. Updates have highlighted a development and product pipeline that includes rapid testing platforms for COVID-19, influenza, tuberculosis (TB) and other viruses, as well as work in molecular assay design and a TB programme.
Investors following GLABF news will see announcements on strategic partnerships and licensing, such as Gemina’s first technology license with a global diagnostics company and additional diagnostic companies entering non-disclosure agreements to evaluate Gemina technologies. The company has also issued strategic updates on its efforts in lateral flow diagnostics, intellectual property development, and plans for a GMP protein production facility in Vancouver, Canada.
Gemina’s news releases also cover capital markets and financing activities, including private placement offerings, changes in planned financings, and a planned non-brokered private placement of secured, non-convertible debentures. In addition, the company has announced that it intends to voluntarily delist its common shares from the Canadian Securities Exchange, subject to approvals and conditions, while remaining a reporting issuer under Canadian securities legislation.
By reviewing the GLABF news stream, readers can track how Gemina communicates its progress in diagnostics technology, commercial partnerships, manufacturing plans and listing or financing decisions over time.
Gemina Laboratories (CSE:GLABF) announced a non‑brokered private placement of secured, non‑convertible debentures to raise a minimum of $1,000,000 and up to $3,000,000, and its intention to voluntarily delist common shares from the Canadian Securities Exchange.
Each debenture has a $1,000 principal, 12‑month maturity, 18% per annum interest compounded monthly, secured by a first‑priority security interest in the company’s intellectual property, and may be prepaid at 105% of principal. Majority debenture holders would get rights to appoint at least 50% of the board and approve material new liabilities. Proceeds are intended to repay secured debt including a $240,110 shareholder loan and for working capital. Offerings may close to Jan 15, 2026; delisting vote is planned at an annual meeting around Feb 13, 2026.
Gemina Laboratories (CSE:GLAB) announced the termination of its previously announced non-brokered private placement that aimed to raise up to $7 million at $0.75 per common share. The company was unable to secure subscriptions and is now exploring alternative financing options.
Additionally, the company announced the departure of two board members, Martha Najib and Bola Grace. The company is currently evaluating alternative financing strategies to address its capital needs.
Gemina Laboratories (CSE:GLAB, OCTQB:GLABF) has announced a non-brokered private placement offering of up to 9,333,333 common shares at $0.75 per share, aiming to raise gross proceeds of up to $7,000,000. The funds will be used to accelerate platform development, expand production, support business development and commercialization activities, and provide working capital. The securities issued will have a four-month and one-day statutory hold period in Canada.
Gemina Laboratories has provided a strategic update for H1 2024, highlighting key achievements and future plans. The company signed its first license deal with a global diagnostics company in April, signaling commercial validation. It is also in advanced discussions with four other significant diagnostics firms. In June, Gemina issued its first commercial invoice, with revenues expected to ramp up in 2025. The company continues to innovate, with a strong R&D team developing new products and solutions. Gemina's new protein production facility is set to open in August, and the company has expanded its market presence to the U.S. by listing on the OTCQB under ticker GLABF.
Gemina Laboratories (OTCQB: GLABF) has commenced trading on the OTCQB Venture Market in the United States. This move aims to expand the company's investor reach, build visibility, increase liquidity, and diversify its shareholder base. Gemina's shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol 'GLAB' and the Frankfurt Exchange under '817'. CEO Brian Firth is optimistic that this expansion will complement their existing listings and facilitate a streamlined approach for US investors to trade their shares. Investors can access real-time quotes and financial disclosures on the OTC Markets website.
Gemina Laboratories Ltd. (CSE:GLAB, OTC:GLABF) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. CEO Brian Firth will present both virtually and in-person, with the presentation available online starting at 7:00 a.m. EST. Gemina specializes in biosensor technology and diagnostics, focusing on rapid testing for pathogens affecting health, including COVID-19. A replay of the presentation will be accessible for 30 days.
Gemina Laboratories Ltd. (CSE:GLAB, OTC:GLABF) has appointed Brian Firth as its new Chief Executive Officer, transitioning from an R&D focus to a revenue-driven model. Firth, with extensive experience in point-of-care diagnostics, previously held leadership roles at Swiss Precision Diagnostics and founded The Health Works Ltd. His appointment is viewed as a significant step towards growth, with plans to launch revenue-generating products. Concurrently, founding CEO John Davies becomes Chairman of the Board. Firth's stock options include performance milestones and a vesting schedule starting September 7, 2023.